Skip to main content

Table 1 Participants’ clinical characteristics

From: Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical score

Characteristic With ovarian function (n = 34) Without ovarian function (n = 56) P value
Age [% (years)]    0.002
 ≥40 (n = 67) 19 (28.4) 48 (71.6)  
 <40 (n = 23) 15 (65.2) 8 (34.8)  
BMI (kg/m2, mean ± SD)    0.136
 <24 (n = 65) 21 (32.3) 44 (67.7)  
 24–28 (n = 20) 12 (60.0) 8 (40.0)  
 ≥28 (n = 5) 1 (20) 4 (80)  
Menarche age (years, mean ± SD) 13.6 ± 1.5 13.8 ± 1.5 0.692
No. of pregnancies (mean ± SD) 2.7 ± 1.5 2.8 ± 1.4 0.918
No. of births (mean ± SD) 1.1 ± 0.3 1.2 ± 0.6 0.414
Pathological classification (%)    0.450
Ductal carcinoma (n = 82) 31 (37.8) 51 (62.2)  
Adenocarcinoma (n = 2) 0 (0) 2 (100.0)  
Lobular carcinoma (n = 6) 3 (50.0) 3 (50.0)  
Histological classification (%)    0.160
 1 (n = 2) 0 (0) 2 (100.0)  
 2 (n = 35) 11 (31.4) 24 (68.6)  
 3 (n = 53) 23 (43.4) 30 (56.6)  
Tumor size    0.013
 T1 (n = 28) 15 (53.6) 13 (46.4)  
 T2 (n = 52) 18 (34.6) 34 (56.4)  
 T3 (n = 10) 1 (10.0) 9 (90.0)  
Lymph node stage    0.023
 N0 (n = 20) 9 (45.0) 11 (55.0)  
 N1 (n = 26) 15 (57.7) 11 (42.3)  
 N2 (n = 18) 4 (22.2) 14 (77.8)  
 N3 (n = 26) 6 (23.1) 20 (76.9)  
ER status    0.839
 ER+ (n = 84) 31 (36.9) 53 (63.1)  
 ER− (n = 6) 3 (50.0) 3 (50.0)  
PR status    1.000
 PR+ (n = 78) 29 (37.2) 49 (62.8)  
 PR− (n = 12) 5 (41.7) 7 (58.3)  
HER-2 score (%)    0.515
 0 (n = 59) 21 (35.6) 38 (64.4)  
 1 (n = 10) 5 (50.0) 5 (50.0)  
 2 (n = 13) 3 (23.1) 10 (76.9)  
 3 (n = 8) 5 (62.5) 3 (37.5)  
Targeted therapy (%) 3 (33.3) 6 (66.7) 1.000
Chemotherapy regimens (%)    0.734
 Taxanes (n = 1) 0 (0) 1 (100.0)  
 Anthracycline or cyclophosphamide (n = 31) 12 (38.7) 19 (61.3)  
 Both anthracycline and cyclophosphamide (n = 58) 22 (37.9) 36 (62.1)  
Chemotherapy cycle (mean ± SD) 6.5 ± 1.2 6.5 ± 1.3 0.676
Duration of tamoxifen (month, mean ± SD) 14.0 ± 13.0 9.9 ± 12.6 0.035
Duration between completing chemotherapy and ovariectomy (month, mean ± SD) 14.7 ± 12.7 10.7 ± 12.2 0.046
Ovarian cyst (%) 15 (44.1) 6 (10.7) <0.001
Metastatic tumor of breast cancer (n = 1) 1 (100) 0 (0)  
Benign epithelial tumor (n = 10) 4 (40) 6 (60)  
Functional cysts (n = 10) 10 (100) 0 (0)  
FSH
(IU/L, mean ± SD)
26.0 ± 2.0 45.2 ± 23.9 <0.001
LH
(IU/L, mean ± SD)
15.2 ± 10.2 24.2 ± 12.1 <0.001
E2
(pg/ml, mean ± SD)
156.3 ± 311.7 19.6 ± 57.4 0.002